The designation C6orf113 inhibitors suggests a class of compounds aimed at inhibiting the function of a protein encoded by a gene labeled C6orf113. The abbreviation "orf" in C6orf113 stands for "open reading frame," indicating a segment of DNA found on chromosome 6 that has the to be translated into a protein. Genes with such orf-designations are typically those whose functions are not yet fully characterized.
Should research eventually identify the protein product of the C6orf113 gene and delineate a critical biological function that makes it a valid target for inhibition, the development of inhibitors would follow a series of standard steps. Initially, a deep analysis of the protein's structure and function would be necessary. This could involve various techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy to elucidate its three-dimensional structure. Understanding the protein's active site, substrate specificity, or allosteric sites would be pivotal in creating molecules that can bind to these sites and inhibit the protein's activity. The binding could be competitive, with the inhibitor molecules mimicking the substrate and blocking its access to the active site, or non-competitive, where the inhibitor binds to a different part of the protein, causing a conformational change that reduces its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor which may indirectly affect ZFUP1 levels by altering protein degradation pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that could lead to altered ubiquitin-proteasome system functioning, potentially impacting ZFUP1 expression. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor, which could affect ZFUP1 expression by dysregulating proteasome-mediated protein turnover. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin selectively inhibits the proteasome, which may lead to disruptions in the degradation pathways that include ZFUP1. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a selective proteasome inhibitor that might influence the expression of proteins involved in ubiquitination, such as ZFUP1. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
IXAZOMIB is an oral proteasome inhibitor which could impact ZFUP1 expression by altering protein degradation mechanisms. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib, an inhibitor of the proteasome, could affect the ubiquitin-proteasome system, potentially influencing ZFUP1 levels. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
PR-619 is a broad-spectrum deubiquitinase inhibitor which may lead to increased ubiquitination and decreased expression of ZFUP1. | ||||||
P22077 | 1247819-59-5 | sc-478536 | 10 mg | $165.00 | ||
P22077 is a specific inhibitor of USP7 and USP47 deubiquitinases but may have off-target effects on ZFUP1 expression or activity. | ||||||